High Q Technologies, based in Waterloo, Ontario, develops quantum‑sensing EPR systems that empower structural biologists, pharmaceutical researchers, and biotechnology teams with high‑resolution, ground‑truth insights into protein behavior. Our flagship instrument, FATHOM®, is the world’s first quantum‑sensing EPR spectrometer, purpose‑built to reveal protein conformations, distance distributions, and dynamics with a level of industry accessible precision unattainable through conventional techniques.

FATHOM’s innovative resonator design and automated workflows streamline operation across multiple samples, dramatically reducing acquisition times while capturing protein motions that are often invisible to traditional structural methods. These capabilities make FATHOM a powerful complement to Cryo‑EM, AlphaFold predictions, and molecular dynamics simulations, providing experimental validation that strengthens mechanistic understanding.

For pharmaceutical drug discovery teams, FATHOM provides differentiated, quantum‑enabled experimental validation that sharpens decision‑making. By confirming mechanism engagement, exposing state‑specific liabilities often missed by conventional assays, and improving compound prioritization, FATHOM reduces the risk of advancing molecules with hidden mechanistic flaws. This iterative feedback improves decision quality across hit validation and lead optimization, enabling drug discovery teams to progress candidates with greater confidence.

At the intersection of AI drug design, experimental structural biology, and proprietary training data, High Q Technologies and the FATHOM platform deliver quantum‑enabled ground‑truth capability. The next bottleneck in AI‑driven drug discovery is determining which AI‑designed molecules actually produce the intended biological mechanism. FATHOM provides an iterative experimental feedback layer that enhances mechanism confidence, improves compound ranking, and reveals state‑specific risk flags across in-silico hit validation and lead optimization. This strengthens candidate selection before substantial downstream development resources are committed, helping partners mitigate a significant driver of late‑stage clinical failure.

To support researchers who do not yet have in‑house EPR capabilities, High Q Technologies also offers a Sample Measurement Service (SMS). This flexible, low friction service readily provides access to FATHOM analysis’, from a single‑sample project to fully managed measurement pipelines, allowing teams to integrate FATHOM’s experimental insights directly into their discovery workflows.

For more information, visit www.highqtechnologies.com.